Characteristics of Fasting in Ramadan in Type 2 Diabetes Patients on Empagliflozin in the DAR Global Surveys of 2020 and 2022
Abstract
Abstract Background The safety of Ramadan fasting in individuals is determined by an interplay between Ramadan, patients, and medication factors. Objective To analyze the challenges associated with Ramadan fasting among patients with diabetes treated with Empagliflozin and other antiglycemic agents who participated in the Diabetes and Ramadan (DAR) global surveys of 2020 and 2022. Methods Building on data from the DAR Global surveys, a sub-analysis was performed on patients treated with Empagliflozin ( n = 1,464) to reflect on the patients' experience and to analyze the challenges associated with Ramadan fasting. The observational survey was conducted in five geographic regions (Gulf countries, Maghreb countries, Middle East [Egypt, Türkiye, and Iraq], Indian subcontinent, and Southeast Asia) in Muslim type 2 diabetes patients post-Ramadan 2020 and 2022. The patients were divided into four groups: Those treated with (1) Empagliflozin without sulphonylureas or insulins, (2) Empagliflozin plus sulphonylureas, (3) Empagliflozin plus insulins, and (4) Empagliflozin plus sulphonylureas and insulins. Descriptive statistics on medical data and baseline demographics were generated, and odds ratios regarding symptomatic hyper- and hypoglycemic events were calculated. The fasting behavior as well as diabetes management of the patients were evaluated. Results Despite having diabetes, a large proportion of patients fasted during Ramadan. Patients treated with Empagliflozin without…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.